Vinpocetine-Sar - instructions for use, dose, side effects, contraindications

Improves the metabolism of the brain, increasing the intake of glucose and oxygen by brain tissue. Increases the resistance of brain cells to hypoxia, facilitating the transport of oxygen and substrates of energy supply to tissues (due to reduced affinity for erythrocytes, increased absorption and metabolism of glucose,switching it to an energetically more advantageous aerobic direction). It promotes the accumulation in the tissues of cyclic adenosine monophosphate and adenosine triphosphate (inhibition of calcium-dependent ions, PDE and stimulation of adenylate cyclase), an increase in the content of catecholamines in the brain tissues. Stimulates the ascending branch of the noradrenergic system, has an antioxidant effect.

The vasodilating effect is associated with a direct relaxing effect on the smooth muscles of the vessels of the predominantly brain. Vinpocetine does not cause the phenomenon of "stealing", primarily enhances the blood supply of the ischemic region of the brain, without changing the blood supply of intact areas. It improves microcirculation in the brain due to a decrease in platelet aggregation, a decrease in blood viscosity, and an increase in the deformability of erythrocytes.

Increases cerebral blood flow; reduces the resistance of cerebral vessels without significant effect on the parameters of the systemic circulation (blood pressure (BP), MO, heart rate).

Pharmacokinetics:The therapeutic concentration for parenteral administration in plasma is 10-20 ng / ml; volume of distribution - 5,3 l / kg. Easily penetrates through the histohematological barriers (including the blood-brain barrier). Penetrates into breast milk (0.25% within the first hour), through the placental barrier. The half-life of the drug is 4.74-5 hours. It is excreted by the kidneys and intestines in a ratio of 3: 2. Link with proteins - 66%, clearance - 66.7 l / h, exceeds the plasma volume of the liver (50 l / h), which indicates an extrahepatic metabolism.

Indications:Neurology: as a symptomatic agent for various forms of cerebral circulatory insufficiency (ischemic stroke, restorative stage of hemorrhagic stroke, consequences of a stroke, transient ischemic attack, vascular dementia, vertebrobasilar insufficiency, cerebrovascular atherosclerosis, posttraumatic and hypertensive encephalopathy).

Ophthalmology: chronic vascular diseases of the choroid and retina (including occlusion of the central artery or retinal vein)

Perceptive hearing loss, Meniere's disease, idiopathic tinnitus.

Contraindications:Hypersensitivity, acute phase of hemorrhagic stroke, severe ischemic heart disease (CHD), severe heart rhythm disturbances, pregnancy, lactation period, age before 18 years.

Carefully:With caution apply the drug with arrhythmia, angina pectoris, unstable arterial pressure and reduced vascular tone. With hemorrhagic cerebral stroke, parenteral administration of vinpocetine is allowed only after the reduction of acute events - usually after 5-7 days.

Pregnancy and lactation:The use of the drug is contraindicated.

Dosing and Administration:

Intravenously drip (infusion rate should not exceed 80 cap / min).

The initial daily dose is 20 mg (in 0.5-1 L of a 0.9% solution of sodium chloride or solutions, containing dextrose). The average daily dose at a body weight of 70 kg is 50 mg. With good tolerance for 2-3 days, the dose is raised to the maximum - 1 mg / kg / day. The course of treatment is 10-14 days. Parenteral, as a rule, used in acute cases to improve the clinical picture, then switch to taking the drug in the form of tablets. Subcutaneous administration of the drug is not allowed.

After achieving the improvement, they switch to taking the drug inside.

Side effects:

FROMo cardiovascular system: changes in the electrocardiogram (segment depression ST, interval lengthening QT); tachycardia, extrasystole (cause-and-effect relationship not established), lability of blood pressure (often decrease).

From the central nervous system: sleep disturbance (insomnia, increased drowsiness); dizziness, headache, general weakness (may be a manifestation of the underlying disease).

From the digestive system: dry mouth, nausea, heartburn.

Other: skin allergic reactions, increased sweating, skin hyperemia, phlebitis with intravenous administration.

Overdose:Overdose of Vinpocetine may be accompanied by a dose-dependent increaseof the side effects of the drug. Treatment consists in the use of antihypertensive and antiarrhythmic drugs under the supervision of a doctor.

Interaction:

Concentrate for the preparation of a solution for infusions is pharmaceutically incompatible with heparin, solutions containing amino acids.

It is possible to intensify the hypotensive effect with simultaneous application with methyldopa (blood pressure control is necessary).

Despite the lack of data confirming the possibility of interaction, it is advisable to use caution when used with drugs (drugs) that affect the central nervous system, antiarrhythmics and anticoagulants.

Special instructions:

In the case of the initial extension of the Q-T interval, as well as with simultaneous application with drugs extending the Q-T interval, periodic ECG monitoring is necessary during the treatment with vinpocetine.

Effect on the ability to drive transp. cf. and fur:During the use of the drug should be careful when driving by transport and working with complex mechanisms.

Form release / dosage:Concentrate for the preparation of solution for infusions 5 mg / ml.

Packaging:

2 ml into neutral glass ampoules.

5 ampoules are placed in a contour mesh package made of a polyvinyl chloride film.

1 or 2 contour squares are placed in a pack of cardboard.

5, 10 ampoules are placed in a pack of cardboard with baffles or lattices, or a cardboard separator.

10 ampoules are placed in a box of cardboard.

Each instruction pack or box is supplied with instructions for use, an ampoule knife or ampoule scarifier.

In the case of using ampoules with notches, kink rings or fracture points, the ampoule knife or ampoule ampoule opener is not inserted.

Storage conditions:In dry, sheltered from light and out of the reach of children, temperature not higher than 25 ° С.

Shelf life:2 years. Do not use after expiry date.

Terms of leave from pharmacies:On prescription

Registration number:P N002623 / 01-2003

Date of registration:08.07.2008 / 10.10.2011

Expiration Date:Unlimited

The owner of the registration certificate:Promomed Rus, Open CompanyPromomed Rus, Open Company Russia

Manufacturer: & nbsp

BIOCHEMIST, OJSC Russia

Representation: & nbspBIOCHEMICAL JSC BIOCHEMICAL JSC Russia

Information update date: & nbsp19.02.2017

Illustrated instructions

Instructions

Vinpocetine-Sar (Vinpocetine - Sar)